Immunic (IMUX) Stock
Small biotech company developing immune system treatments. Here's the price, business snapshot, and what's worth knowing about Immunic in July 2026.
Immunic Inc (IMUX) is a small-cap biotechnology company with a market capitalisation of about $81.12 million. As a company in the biotech space, its prospects tend to be driven by clinical results, regulatory decisions, partnerships and financing activity rather than steady earnings. That makes IMUX inherently more speculative and often more volatile than larger, diversified firms. Investors should focus on the company’s latest regulatory filings, press releases and cash runway, since small biotechs frequently need to raise capital to fund development. Potential upside may come from positive trial readouts or strategic collaborations, while downside risks include trial failures, regulatory setbacks and dilution from new funding. This summary is educational only; it is not personal financial advice. Consider your risk tolerance and consult an authorised financial professional before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immunic Inc.'s stock, expecting its price to rise significantly.
Financial Health
Immunic Inc. is showing strong cash flow and solid book value, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IMUX
Oncology Repurposing: Could Autoimmune Buyouts Surge?
Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published: 24 March 2026
Explore BasketTYK2 Inhibitors: Might Oral Drugs Rule Autoimmune?
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
Published: 7 January 2026
Explore BasketRinvoq vs Humira Results | Immunology Market Shift
AbbVie's new arthritis drug, Rinvoq, has proven superior to its predecessor, Humira, signaling a major shift in the immunology market. This theme focuses on the innovative pharmaceutical companies poised to benefit from the demand for more effective autoimmune disease treatments.
Published: 21 October 2025
Explore BasketPharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: 29 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Potential Growth Drivers
Clinical readouts, approvals or partnerships can materially change outlook, though these events are uncertain and can go either way.
Catalysts To Watch
Upcoming trial milestones or financing announcements are common catalysts; they may boost momentum or increase volatility.
Market & Funding Context
Small-cap biotechs often need fresh capital to progress programmes — check cash runway and dilution risk before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
